CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
